Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Yen, Swiss franc rally on global outlook risks after hawkish Powell

11/30/2021 | 04:34pm EST
FILE PHOTO: A picture illustration of  U.S. dollar Swiss Franc British pound and Euro bank notes

NEW YORK (Reuters) - The safe-haven yen and Swiss Franc gained on Tuesday, with risk appetite plummeting, as investors grew nervous about a suddenly hawkish Federal Reserve that could deliver aggressive rate hikes and derail a nascent economic recovery.

Worries about the new Omicron coronavirus variant also kept a bid in these safe-haven currencies.

The dollar, on the other hand, retreated on Tuesday after rising when Fed Chair Jerome Powell said the risk of inflation had increased and suggested retiring the term "transitory" to describe the surge in prices. He also pushed for accelerating the tapering of Fed asset purchases.

His comments suggested an urgency to undertake quick monetary policy action that financial markets may not be prepared for, analysts said.

"Overall, the risks to the short-term outlook keep on growing. Investors have always viewed the Fed as the safety net, but the Fed looks like its panicking here," said Edward Moya, senior market analyst, at OANDA in New York.

"The Fed was wrong on inflation. And now it appears they're going to rush tapering and quickly deliver rate hikes. And if the inflationary pressure remains, you could see an accelerated rate hike cycle that could threaten financial conditions."

In late trading, the dollar fell 0.4% against the yen to 113.065 yen.

Against the Swiss franc, the dollar dropped 0.4% to 0.9185 francs.

The dollar index fell 0.3% to 95.90. It rallied earlier, while U.S. stocks fell, after Powell's hawkish remarks.

"Traders are in 'sell first and ask questions later' mode," said Karl Schamotta, chief market strategist at Cambridge Global Payments in Toronto.

Earlier, the yen and Swiss franc rose against the dollar, after Moderna's CEO said the coronavirus vaccines will likely be less effective against the Omicron variant as they have been against other variants.

Adding to the fears, drugmaker Regeneron Pharmaceuticals Inc said on Tuesday its COVID-19 antibody treatment could be less effective against Omicron.

The warnings reinforced a view that the global economy could take longer to return to pre-pandemic levels than many had been expecting.

Against the U.S. dollar, the euro rose 0.4% to$1.1335, posting its biggest three-day rising streak since December 2020.

Prior to Omicron's arrival, the main driver of currency moves was how traders perceived the different speeds at which global central banks would end pandemic-era stimulus and raise interest rates as they looked to combat rising inflation without choking off growth.

Cryptocurrencies also had a volatile trading session. Ethereum was last up 4.8% at $4,668. Bitcoin was down 0.3% at $57,645.

Graphic: World FX rates https://graphics.reuters.com/GLOBAL-CURRENCIES-PERFORMANCE/0100301V041/index.html

Currency bid prices at 4:11PM (2111 GMT)

Description RIC Last U.S. Close Pct Change YTD Pct High Bid Low Bid

Previous Change


Dollar index 95.8590 96.1990 -0.34% 6.532% +96.6470 +95.5440

Euro/Dollar $1.1340 $1.1293 +0.44% -7.17% +$1.1387 +$1.1235

Dollar/Yen 113.0350 113.5300 -0.45% +9.38% +113.8900 +112.5350

Euro/Yen 128.19 128.19 +0.00% +1.00% +128.6000 +127.6500

Dollar/Swiss 0.9181 0.9227 -0.49% +3.78% +0.9266 +0.9158

Sterling/Dollar $1.3306 $1.3318 -0.06% -2.58% +$1.3370 +$1.3195

Dollar/Canadian 1.2775 1.2738 +0.29% +0.32% +1.2837 +1.2732

Aussie/Dollar $0.7130 $0.7143 -0.19% -7.32% +$0.7170 +$0.7063

Euro/Swiss 1.0411 1.0418 -0.07% -3.66% +1.0444 +1.0391

Euro/Sterling 0.8520 0.8477 +0.51% -4.67% +0.8538 +0.8474

NZ $0.6827 $0.6825 +0.02% -4.94% +$0.6856 +$0.6773


Dollar/Norway 9.0360 9.0455 -0.12% +5.21% +9.1260 +9.0080

Euro/Norway 10.2458 10.1786 +0.66% -2.11% +10.3158 +10.1737

Dollar/Sweden 9.0179 9.0594 -0.06% +10.02% +9.1103 +9.0069

Euro/Sweden 10.2270 10.2336 -0.06% +1.49% +10.3036 +10.2077

(Reporting by Caroline Valetkevitch and Gertrude Chavez-Dreyfuss; Additional reporting by Saikat Chatterjee in London; Editing by Bernadette Baum and David Gregorio)

By Caroline Valetkevitch and Gertrude Chavez-Dreyfuss

ę Reuters 2021
12:01pForty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talen..
09:31aFda accepts for review libtayo in combination with chemotherapy for first-line treatmen..
01/19Regeneron Says US FDA Accepts for Review its Supplemental BLA for Libtayo in Combinatio..
01/19Regeneron Says FDA to Review Libtayo/Chemotherapy Combo in First-Line NSCLC Treatment
01/19FDA Accepts for Review Libtayo« (cemiplimab-rwlc) in Combination with Chemotherapy for ..
01/19FDA Accepts for Review Libtayo« (cemiplimab-rwlc) in Combination with Chemotherapy for ..
01/19Sanofi, Regeneron Say Dupixent Significantly Reduces Itching in Prurigo Nodularis Patie..
01/19Sanofi-Regeneron's Dermatitis Drug Lowers Itch, Skin Lesions In Late-Stage Trial
01/19Second Positive Phase 3 Dupixent« (dupilumab) Trial Confirms Significant Improvements f..
01/18Morgan Stanley Adjusts Regeneron Pharmaceuticals Price Target to $585 From $617, Mainta..
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 15 515 M - -
Net income 2021 7 967 M - -
Net cash 2021 4 180 M - -
P/E ratio 2021 8,78x
Yield 2021 -
Capitalization 64 627 M 64 627 M -
EV / Sales 2021 3,90x
EV / Sales 2022 4,30x
Nbr of Employees 9 766
Free-Float 81,7%
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 618,11 $
Average target price 697,73 $
Spread / Average Target 12,9%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
WUXI APPTEC CO., LTD.-6.39%51 406
BIONTECH SE-37.29%39 044
BEIGENE, LTD.-12.58%24 335